Table 2.
Prognostic factors for overall survival according to univariate and multivariate analyses in patients with both wild-type and mutant KRAS metastatic colorectal cancer after colorectal liver metastasectomy
| n = 220 | Univariate | Multivariate | ||
|---|---|---|---|---|
| Variable | Hazard ratios (95% CI) | P-value | Hazard ratios (95% CI) | P-value |
| Age > 65 (y/o) | 1.055 (0.729–1.526) | 0.778 | — | — |
| Initial stage IV at diagnosis | 1.668 (1.129–2.462) | 0.010 | 1.336 (0.885–2.016) | 0.168 |
| Bilobar liver metastases | 1.494 (0.902–2.475) | 0.119 | — | — |
| Size > 5 cm | 1.268 (0.803–2.002) | 0.309 | — | — |
| Number > 3 | 1.932 (1.287–2.903) | 0.002 | 1.753 (1.151–2.670) | 0.009 |
| High grade | 1.385 (0.915–2.096) | 0.123 | — | — |
| Margin R2 | 3.112 (1.350–7.172) | 0.008 | 2.087 (1.200–6.567) | 0.017 |
| Extrahepatic metastasis | 1.462 (0.937–2.282) | 0.094 | 1.255 (0.798–1.973) | 0.326 |
| CIP2A overexpression | 1.447 (1.001–2.092) | 0.049 | 1.373 (0.946–1.992) | 0.096 |
Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog.